Zavegepant Hydrochloride

CHEMBL4650220 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
675.3 g/mol
LogP
Phase
4

Zavegepant hydrochloride is the hydrochloride salt form of zavegepant, an intranasal CGRP receptor antagonist for acute migraine treatment. The hydrochloride salt form provides appropriate physicochemical properties for the aqueous intranasal spray formulation. Like the free base, it blocks CGRP receptors in trigeminal afferents and meningeal blood vessels to abort acute migraine attacks.

Молекулярная масса

675,3000 g/mol

TPSA

117,00 Ų

Механизм действия

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12.Cl

InChI

InChI=1S/C36H46N8O3.ClH/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45;/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47);1H/t32-;/m1./s1

Molecular Formula

C36H47ClN8O3

HBD / HBA

4 / 6

Вращаемые Связи

6

Тяжёлые Атомы

48

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Zavegepant hydrochloride is the hydrochloride salt form of zavegepant, an intranasal CGRP receptor antagonist for acute migraine treatment. The hydrochloride salt form provides appropriate physicochemical properties for the aqueous intranasal spray formulation. Like the free base, it blocks CGRP receptors in trigeminal afferents and meningeal blood vessels to abort acute migraine attacks.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Zavegepant Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650220. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 134819878. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.